by E Datan · 2020 · Cited by 16 — A second-generation glucose- triptolide conjugate ( glutriptolide -2) was developed. Glutriptolide -2 exhibits selective toxicity to cancer cells over normal cells.

by S Bao · 2024 · Cited by 18 — Another TPL analog , (5R)-5-hydroxytriptolide (LLDT-8), is a low - toxicity immunosuppressant currently in phase I clinical trials [203]. LLDT-8 ...

by L Wu · 2023 · Cited by 3 — CX-23 can prevent DDP-resistant lung cancer progression without causing any toxicity in the liver, kidneys, or lungs after 6 weeks of treatment.

by P Noel · 2019 · Cited by 279 — LLDT-288, a C14b-heterocycle aminomethyl substituent. TPL analog , exhibited promising efficacy with extremely low toxicity in a xenograft mouse model of ...

by W Gang · 2022 · Cited by 6 — finding triptolide analogs which are easy to deliver, have lower toxicity , and consist of drug-like properties either by synthetic.

Triptolide itself is too toxic to be a viable therapeutic option, but if less toxic triptolide analogues show similar radioprotective roles, they may prove ...

by Q Tian · 2023 · Cited by 14 — ... toxicity have limited its. 87 clinical development, and a number of analogs of triptolide have been developed for improved clinical. 88.

by D Fan · 2018 · Cited by 124 — However, its multiorgan toxicity prevents it from being widely used in clinical practice. Recently, several attempts are being performed to reduce TP toxicity .

Oct 22, 2024 — Triptolide γ-lactone and C-14 analogues were prepared and evaluated cytotoxity against human lung adenocarcinoma epithelial A549 cells and human ...

This high-purity compound is a potent inhibitor of NF-κB activation, making it invaluable for pharmaceutical research, oncology studies, and anti-inflammatory ...